Cargando…

Frailty Status and Polypharmacy Predict All-Cause Mortality in Community Dwelling Older Adults in Europe

European population ageing is associated with frailty, a complex geriatric syndrome, and polypharmacy, both resulting in adverse health outcomes. In this study we aimed to evaluate the impact of frailty and polypharmacy, on mortality rates, within 30 months, using a cohort of SHARE participants aged...

Descripción completa

Detalles Bibliográficos
Autores principales: Midão, Luís, Brochado, Pedro, Almada, Marta, Duarte, Mafalda, Paúl, Constança, Costa, Elísio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036295/
https://www.ncbi.nlm.nih.gov/pubmed/33808273
http://dx.doi.org/10.3390/ijerph18073580
_version_ 1783676876652281856
author Midão, Luís
Brochado, Pedro
Almada, Marta
Duarte, Mafalda
Paúl, Constança
Costa, Elísio
author_facet Midão, Luís
Brochado, Pedro
Almada, Marta
Duarte, Mafalda
Paúl, Constança
Costa, Elísio
author_sort Midão, Luís
collection PubMed
description European population ageing is associated with frailty, a complex geriatric syndrome, and polypharmacy, both resulting in adverse health outcomes. In this study we aimed to evaluate the impact of frailty and polypharmacy, on mortality rates, within 30 months, using a cohort of SHARE participants aged 65 years old or more. Frailty was assessed using a version of Fried’s phenotype criteria operationalized to SHARE while polypharmacy was defined as taking five or more drugs per day. We found a prevalence of 40.4% non-frail, 47.3% pre-frail and 12.3% frail participants. Moreover, a prevalence of polypharmacy of 31.3% was observed, being 3 three times more prevalent in frail individuals and two times in pre-frail individuals, when compared with non-frail. Individuals with both conditions had shown higher mortality rates. Comparing with non-polymedicated non-frail individuals all the other conditions are more prone to die within 30 months. Polymedicated older and male participants exhibited also higher mortality rates. This work shows polypharmacy and frailty to be associated with a higher risk of all-cause of mortality and highlights the need to decrease ‘unnecessary’ polypharmacy to reduce drug-related issues and also the need to assess frailty early to prevent avoidable adverse outcomes.
format Online
Article
Text
id pubmed-8036295
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80362952021-04-12 Frailty Status and Polypharmacy Predict All-Cause Mortality in Community Dwelling Older Adults in Europe Midão, Luís Brochado, Pedro Almada, Marta Duarte, Mafalda Paúl, Constança Costa, Elísio Int J Environ Res Public Health Article European population ageing is associated with frailty, a complex geriatric syndrome, and polypharmacy, both resulting in adverse health outcomes. In this study we aimed to evaluate the impact of frailty and polypharmacy, on mortality rates, within 30 months, using a cohort of SHARE participants aged 65 years old or more. Frailty was assessed using a version of Fried’s phenotype criteria operationalized to SHARE while polypharmacy was defined as taking five or more drugs per day. We found a prevalence of 40.4% non-frail, 47.3% pre-frail and 12.3% frail participants. Moreover, a prevalence of polypharmacy of 31.3% was observed, being 3 three times more prevalent in frail individuals and two times in pre-frail individuals, when compared with non-frail. Individuals with both conditions had shown higher mortality rates. Comparing with non-polymedicated non-frail individuals all the other conditions are more prone to die within 30 months. Polymedicated older and male participants exhibited also higher mortality rates. This work shows polypharmacy and frailty to be associated with a higher risk of all-cause of mortality and highlights the need to decrease ‘unnecessary’ polypharmacy to reduce drug-related issues and also the need to assess frailty early to prevent avoidable adverse outcomes. MDPI 2021-03-30 /pmc/articles/PMC8036295/ /pubmed/33808273 http://dx.doi.org/10.3390/ijerph18073580 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Midão, Luís
Brochado, Pedro
Almada, Marta
Duarte, Mafalda
Paúl, Constança
Costa, Elísio
Frailty Status and Polypharmacy Predict All-Cause Mortality in Community Dwelling Older Adults in Europe
title Frailty Status and Polypharmacy Predict All-Cause Mortality in Community Dwelling Older Adults in Europe
title_full Frailty Status and Polypharmacy Predict All-Cause Mortality in Community Dwelling Older Adults in Europe
title_fullStr Frailty Status and Polypharmacy Predict All-Cause Mortality in Community Dwelling Older Adults in Europe
title_full_unstemmed Frailty Status and Polypharmacy Predict All-Cause Mortality in Community Dwelling Older Adults in Europe
title_short Frailty Status and Polypharmacy Predict All-Cause Mortality in Community Dwelling Older Adults in Europe
title_sort frailty status and polypharmacy predict all-cause mortality in community dwelling older adults in europe
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036295/
https://www.ncbi.nlm.nih.gov/pubmed/33808273
http://dx.doi.org/10.3390/ijerph18073580
work_keys_str_mv AT midaoluis frailtystatusandpolypharmacypredictallcausemortalityincommunitydwellingolderadultsineurope
AT brochadopedro frailtystatusandpolypharmacypredictallcausemortalityincommunitydwellingolderadultsineurope
AT almadamarta frailtystatusandpolypharmacypredictallcausemortalityincommunitydwellingolderadultsineurope
AT duartemafalda frailtystatusandpolypharmacypredictallcausemortalityincommunitydwellingolderadultsineurope
AT paulconstanca frailtystatusandpolypharmacypredictallcausemortalityincommunitydwellingolderadultsineurope
AT costaelisio frailtystatusandpolypharmacypredictallcausemortalityincommunitydwellingolderadultsineurope